XBP1s Mediates Cross-resistance to Combination Treatment of CDK4/6 Inhibitors plus Endocrine Therapy in Breast Cancer.

However, although XBP1 immunoreactivity scores showed a strong trend toward elevation in treatment‐resistant specimens, statistical significance was not reached (Figure 1G ).

also in 5,725 other papers